Latanoprost Completed Phase 4 Trials for Glaucoma, Primary Open Angle (POAG) / Ocular Hypertension Treatment

IndicationsStatusPurposePhase
CompletedTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT02017327Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose
NCT01162603Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
NCT0033057724-Hour Intraocular Pressure (IOP) And Blood Pressure Control In Glaucoma And Ocular Hypertension Patients